A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Carcinoma, Transitional Cell Clinical Trial

Official title:

Open-label, Single-arm Phase II Study of Trastuzumab and Pyrotinib Combination Regimen in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma Refractory to Standard Therapies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05318339
• Other study ID #: NCC3398
• Status: Recruiting
• Phase: Phase 2
• Start date: March 10, 2022
• Est. completion date: December 10, 2024

Study information

• Verified date: March 2022
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A open-label, single-arm, phase II trial to study was designed to evaluate the effectiveness and safety of trastuzumab and pyrotinib in treating HER2 positive patients who have previously treated, locally advanced, or metastatic urothelial carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 10, 2024
• Est. primary completion date: March 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Sign the informed consent form

• Locally advanced or metastatic histologically confirmed transitional cell carcinoma of the urothelium, including the bladder, urethra, ureter, or renal pelvis

• 18 years and older

• HER2 expression (3+ or 2+) as determined by immunohistochemistry or gene amplification by fluorescent in situ hybridization

• Relapsed from or failed at least one prior standard systemic chemotherapy regimen, including immunotherapy, HER2 ADC durgs, and chemothearpy containing cisplatin, carboplatin, paclitaxel, docetaxel, or gemcitabine

• At least 1 measurable lesion could be evaluated by RECIST v1.1

• Performance status: ECOG 0-1

• Life expectancy more than 12 weeks

• Ejection fraction at least 50% (or lower limit of normal) by echocardiogram

• Good organ function:

Blood routine: hemoglobin =80g/L, neutrophil =1.5×10^9/L, platelet =75×10^9/L; Renal function: creatinine=1.5×upper limit of normal (UNL) or creatinine clearance =50ml/min; Liver function: total bilirubin (TBIL)=1.5×upper limit of normal (UNL); ALT=2.5×UNL, AST=2.5×UNL, ALT=5×UNL and AST=5×UNL for patients with liver metastasis

Exclusion Criteria:

• Have received trastuzumab or pyrotinib treatment in the past

• Known to have allergic reactions to any ingredients or excipients of experimental drugs

• Radiotherapy, RFA, interventional therapy or surgery were performed within 28 days before the first medication (except for previous diagnostic biopsy)

• Other active malignant tumors, excluding those who have been disease free for more than 5 years or in situ cancer considered to have been cured by adequate treatment

• Clinically significant ascites

• Brain metastasis or meningeal metastasis with neurological symptoms

• Diabetes was not controlled, defined as HbA1c > 7.5% after anti-diabetic drugs or hypertension was not controlled, defined as systolic / diastolic blood pressure > 140 / 90 mmHg after antihypertensive drug

• Myocardial infarction, severe/unstable angina, New York Heart Association (NYHA) class III or IV congestive heart failure in the past 12 months

• Known to be infected with human immunodeficiency virus (HIV), have acquired immunodeficiency syndrome (AIDS) related diseases, have active hepatitis B or hepatitis C

• Pregnant or nursing

• May increase the risk associated with participation in the study or administration of the study drug or mental illness that may interfere with the interpretation of research results

• There are other serious diseases that the researchers believe patients cannot be included in the study

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• HER-2 Gene Amplification

Intervention

Drug:
• Trastuzumab
A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1. For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks. Pyrotinib 400mg PO daily will be administrated at the same time.

Locations

Country	Name	City	State
China	National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective response rate as assessed by RECIST criteria	1 year
Secondary	OS	Overall survival	From date of initiation of treatment to date of death due to any cause, assessed up to 2 years
Secondary	PFS	Progression free survival	From date of initiation of treatment to date of progression or death due to any cause, whichever occurs first, assessed up to 2 years